Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10x Genomics, Inc. (NASDAQ: TXG) is a life science technology company focused on single cell and spatial biology, and this news page aggregates company-related announcements, research collaborations and financial updates. The company’s integrated research solutions include instruments, consumables and software that are used by academic and translational researchers and biopharmaceutical companies to study complex biological systems.
News about 10x Genomics often highlights developments in its technology platforms, such as new single cell instruments, assays and spatial workflows. Recent announcements have described launches and enhancements within the Chromium single cell portfolio, including instruments and assays designed to make high-performance single cell analysis more accessible and scalable. The company has also reported new capabilities on its Xenium spatial platform, including spatial multiomic workflows that enable simultaneous RNA and protein detection on tissue sections.
Another key theme in TXG news is large-scale research collaborations. 10x Genomics has announced partnerships with academic medical centers, cancer institutes, research consortia and nonprofit organizations to apply its single cell and spatial technologies in areas such as autoimmune disease, oncology, immuno-oncology and transplantation. These initiatives often involve generating high-resolution molecular maps of cells and tissues, linking them with clinical data and exploring potential diagnostic or clinical reporting frameworks.
Investors and researchers following TXG news will also find periodic financial results, preliminary revenue updates and participation in healthcare and investor conferences. Together, these items provide insight into the company’s product adoption, geographic reach, research impact and engagement with the broader scientific and investment communities. Users interested in 10x Genomics can use this page to review company press releases and related coverage over time.
10x Genomics (Nasdaq: TXG) will participate in the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 12:50 p.m. ET. The company's management will engage in a virtual fireside chat to discuss business activities. Interested parties can access the live and archived webcast through the company's website.
Recognized for advancing human health, 10x Genomics provides integrated solutions for biological analysis, widely used by premier research institutions and pharmaceutical companies globally.
10x Genomics (Nasdaq: TXG) announced new product details at its Xperience 2022 virtual event, showcasing innovations in single cell and spatial analysis technologies. Key products include the Chromium Fixed RNA Profiling Kit for improved sample preparation, Visium CytAssist to enhance spatial analysis capabilities, and a preview of the Xenium Analyzer, targeting gene expression at subcellular resolution. The company emphasizes its commitment to advancing human health through groundbreaking technologies, with multiple product launches planned for 2022.
10x Genomics, Inc. (Nasdaq: TXG) reported strong financial results for Q4 and full year 2021, with revenues of $143.5 million for Q4 and $490.5 million for the year, reflecting increases of 28% and 64%, respectively, compared to 2020. Gross margins for Q4 were 81%, slightly down from 83% year-over-year. Significant operating losses decreased to $15.8 million in Q4 from $409.6 million a year earlier. For 2022, the company projects revenues of $600 million to $630 million, indicating 22% to 28% growth.
10x Genomics (Nasdaq: TXG) will release its fourth quarter and full year financial results for 2021 on February 16, 2022. A conference call is scheduled at 1:30 p.m. PT to discuss the results and future outlook. The company's integrated solutions for biological analysis have been widely adopted globally, with significant citations in research. 10x Genomics holds a robust patent portfolio exceeding 1,300 patents.
10x Genomics (Nasdaq: TXG) expanded its 10x Certified Service Provider Network by adding three clinical research organizations: Q2 Solutions, Azenta Life Sciences, and CellCarta. This initiative aims to assist global biopharmaceutical companies in utilizing its advanced single-cell and spatial technologies for drug development. The partnership is designed to help predict therapy resistance in cancer patients and enhance clinical trial outcomes. Established in 2018, the program now includes over 40 service providers worldwide, showcasing an increasing demand for innovative genomic solutions.
ReCode Therapeutics announced the appointment of
10x Genomics (Nasdaq: TXG) announced participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 2:15 p.m. ET. The presentation will be accessible via a live and archived webcast on the company's website. 10x Genomics specializes in life science technology, offering integrated solutions for biological analysis.
Its products are utilized globally, including by top research institutions and pharmaceutical companies. The company boasts over 1,200 patents and has contributed to significant research in areas like oncology and neuroscience.
Summary not available.
10x Genomics (TXG) reported third-quarter 2021 revenue of $125.3 million, marking a 74% increase from the previous year and an 8% rise sequentially. The company launched the Chromium X instrument and increased its installed base, contributing to higher consumables revenue. Operating expenses decreased to $116.7 million, down 5% year-over-year, primarily due to lower R&D expenses. The operating loss improved to $15.9 million from $65.3 million in Q3 2020. Net loss narrowed to $17.2 million compared to $65.8 million a year prior. 2021 revenue guidance was revised to $490-$500 million, indicating 64%-67% growth.
Summary not available.
FAQ
What is the current stock price of 10X Genomics (TXG)?
What is the market cap of 10X Genomics (TXG)?
